{"url_path":"/sec/phio/8-k/2026-07-21/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1533040/0001437749-26-023916-index.html","accession_number":"0001437749-26-023916","cik":"0001533040","ticker":"PHIO","issuer_name":"Phio Pharmaceuticals Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1533040/0001437749-26-023916-index.html","primary_entity_key":"0001533040","primary_entity_name":"Phio Pharmaceuticals Corp."},"word_count":303,"has_tables":true,"body_markdown":"**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nEffective as of July 20, 2026, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed R. Todd Plott, M.D. to serve on the Board until the 2026 annual meeting of stockholders. Dr. Plott was also appointed to serve as a member of the Board’s Governance Committee. Dr. Plott is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory committee member with more than 30 years of experience in dermatologic care and innovation. \n\n \n\nIn connection with Dr. R. Todd Plott, M.D.’s appointment to the Board, Dr. R. Todd Plott, M.D. will enter into the Company’s standard form of indemnification agreement. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify Dr. R. Todd Plott, M.D. for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service on the Board. In addition, Dr. R. Todd Plott, M.D. will receive standard compensation and equity awards available to non-employee directors of the Company. The Company’s non-employee director compensation program is described in the “Director Compensation” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2026.\n\n \n\nThere are no arrangements or understandings between Dr. R. Todd Plott, M.D. and any other persons, pursuant to which Dr. R. Todd Plott, M.D. was appointed to the Board. There are no current or proposed transactions between the Company and Dr. R. Todd Plott, M.D. or his immediate family members that would require disclosure under Item 404(a) of Regulation S-K promulgated by the SEC."}